ShcSH2结构域结合蛋白1(SHCBP1),与Src同源物和胶原蛋白同源物(Shc)的SH2结构域特异性结合的蛋白质,参与各种信号转导途径的调节,据报道,这与肿瘤发生和进展有关。然而,病理机制尚未完全研究。因此,本研究旨在全面阐明SHCBP1在多种癌症类型中的潜在功能.SHCBP1在各种肿瘤中的综合分析,包括基因表达,诊断,预后,免疫相关特征,遗传改变,和功能富集,是基于多个数据库和分析工具进行的。SHCBP1在大多数类型的癌症中上调。qRT-PCR结果证实,SHCBP1mRNA在肺腺癌(LUAD)和肝细胞肝癌(LIHC)细胞系中明显上调。基于接收机工作特性(ROC)和生存分析,SHCBP1被认为是潜在的诊断和预后生物标志物。此外,根据SHCBP1表达与免疫细胞浸润的相关性分析,SHCBP1表达与肿瘤免疫和免疫抑制微环境有关,免疫检查点基因,和免疫相关基因(MHC基因,趋化因子,和趋化因子受体)。此外,SHCBP1表达与肿瘤突变负荷(TMB)相关,微卫星不稳定性(MSI),和新抗原。鉴定了泛癌症中SHCBP1突变景观的特征。最后,我们重点研究SHCBP1在LUAD中的临床意义和潜在的生物学作用。我们的研究全面揭示了SHCBP1可以被鉴定为癌症诊断和预后的免疫相关生物标志物。和肿瘤免疫治疗的潜在治疗靶点。
Shc SH2-domain binding protein 1 (SHCBP1), a protein specific binding to SH2 domain of Src homolog and collagen homolog (Shc), takes part in the regulation of various signal transduction pathways, which has been reported to be associated with tumorigenesis and progression. However, the pathological mechanisms are not completely investigated. Thus, this study aimed to comprehensively elucidate the potential functions of SHCBP1 in multiple cancer types. The comprehensive analyses for SHCBP1 in various tumors, including gene expression, diagnosis, prognosis, immune-related features, genetic alteration, and function enrichment, were conducted based on multiple databases and analysis tools. SHCBP1 was upregulated in most types of cancers. The results of qRT-PCR had confirmed that SHCBP1 mRNA was significantly upregulated in lung adenocarcinoma (LUAD) and liver hepatocellular carcinoma (LIHC) cell lines. Based on the receiver operating characteristic (ROC) and survival analysis, SHCBP1 was considered as a potential diagnostic and prognostic biomarker. Furthermore, SHCBP1 expression was linked with tumor immunity and immunosuppressive microenvironment according to the correlation analysis of SHCBP1 expression with immune cells infiltration, immune checkpoint genes, and immune-related genes (MHC genes, chemokines, and chemokines receptors). Moreover, SHCBP1 expression correlated with tumor mutational burden (TMB), microsatellite instability (MSI), and neoantigens. The feature of SHCBP1 mutational landscape in pan-cancer was identified. Finally, we focused on investigating the clinical significance and the potential biological role of SHCBP1 in LUAD. Our study comprehensively uncovered that SHCBP1 could be identified as an immune-related biomarker for cancer diagnosis and prognosis, and a potential therapeutic target for tumor immunotherapy.